Your browser doesn't support javascript.
loading
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-ß in Alzheimer's disease.
Xia, Zengjie; Prescott, Emily E; Urbanek, Agnieszka; Wareing, Hollie E; King, Marianne C; Olerinyova, Anna; Dakin, Helen; Leah, Tom; Barnes, Katy A; Matuszyk, Martyna M; Dimou, Eleni; Hidari, Eric; Zhang, Yu P; Lam, Jeff Y L; Danial, John S H; Strickland, Michael R; Jiang, Hong; Thornton, Peter; Crowther, Damian C; Ohtonen, Sohvi; Gómez-Budia, Mireia; Bell, Simon M; Ferraiuolo, Laura; Mortiboys, Heather; Higginbottom, Adrian; Wharton, Stephen B; Holtzman, David M; Malm, Tarja; Ranasinghe, Rohan T; Klenerman, David; De, Suman.
Afiliação
  • Xia Z; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
  • Prescott EE; UK Dementia Research Institute at University of Cambridge, Cambridge, UK.
  • Urbanek A; Sheffield Institute for Translational Neuroscience, Division of Neurosciences, University of Sheffield, Sheffield, S10 2HQ, UK.
  • Wareing HE; Sheffield Institute for Translational Neuroscience, Division of Neurosciences, University of Sheffield, Sheffield, S10 2HQ, UK.
  • King MC; Sheffield Institute for Translational Neuroscience, Division of Neurosciences, University of Sheffield, Sheffield, S10 2HQ, UK.
  • Olerinyova A; Sheffield Institute for Translational Neuroscience, Division of Neurosciences, University of Sheffield, Sheffield, S10 2HQ, UK.
  • Dakin H; Sheffield Institute for Translational Neuroscience, Division of Neurosciences, University of Sheffield, Sheffield, S10 2HQ, UK.
  • Leah T; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
  • Barnes KA; UK Dementia Research Institute at University of Cambridge, Cambridge, UK.
  • Matuszyk MM; Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK.
  • Dimou E; Sheffield Institute for Translational Neuroscience, Division of Neurosciences, University of Sheffield, Sheffield, S10 2HQ, UK.
  • Hidari E; Sheffield Institute for Translational Neuroscience, Division of Neurosciences, University of Sheffield, Sheffield, S10 2HQ, UK.
  • Zhang YP; Sheffield Institute for Translational Neuroscience, Division of Neurosciences, University of Sheffield, Sheffield, S10 2HQ, UK.
  • Lam JYL; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
  • Danial JSH; UK Dementia Research Institute at University of Cambridge, Cambridge, UK.
  • Strickland MR; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
  • Jiang H; UK Dementia Research Institute at University of Cambridge, Cambridge, UK.
  • Thornton P; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
  • Crowther DC; UK Dementia Research Institute at University of Cambridge, Cambridge, UK.
  • Ohtonen S; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
  • Gómez-Budia M; UK Dementia Research Institute at University of Cambridge, Cambridge, UK.
  • Bell SM; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
  • Ferraiuolo L; UK Dementia Research Institute at University of Cambridge, Cambridge, UK.
  • Mortiboys H; SUPA School of Physics and Astronomy, University of St Andrews, North Haugh, St Andrews, KY16 9SS, UK.
  • Higginbottom A; Department of Neurology, Hope Center for Neurological Disorders, Knight ADRC, Washington University School of Medicine, St. Louis, MO, USA.
  • Wharton SB; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Holtzman DM; Department of Neurology, Hope Center for Neurological Disorders, Knight ADRC, Washington University School of Medicine, St. Louis, MO, USA.
  • Malm T; Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Ranasinghe RT; Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Klenerman D; A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
  • De S; A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Nat Commun ; 15(1): 4695, 2024 Jun 01.
Article em En | MEDLINE | ID: mdl-38824138
ABSTRACT
Which isoforms of apolipoprotein E (apoE) we inherit determine our risk of developing late-onset Alzheimer's Disease (AD), but the mechanism underlying this link is poorly understood. In particular, the relevance of direct interactions between apoE and amyloid-ß (Aß) remains controversial. Here, single-molecule imaging shows that all isoforms of apoE associate with Aß in the early stages of aggregation and then fall away as fibrillation happens. ApoE-Aß co-aggregates account for ~50% of the mass of diffusible Aß aggregates detected in the frontal cortices of homozygotes with the higher-risk APOE4 gene. We show how dynamic interactions between apoE and Aß tune disease-related functions of Aß aggregates throughout the course of aggregation. Our results connect inherited APOE genotype with the risk of developing AD by demonstrating how, in an isoform- and lipidation-specific way, apoE modulates the aggregation, clearance and toxicity of Aß. Selectively removing non-lipidated apoE4-Aß co-aggregates enhances clearance of toxic Aß by glial cells, and reduces secretion of inflammatory markers and membrane damage, demonstrating a clear path to AD therapeutics.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apolipoproteínas E / Peptídeos beta-Amiloides / Apolipoproteína E4 / Doença de Alzheimer Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apolipoproteínas E / Peptídeos beta-Amiloides / Apolipoproteína E4 / Doença de Alzheimer Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article